An FDA Act that may be relvant to ATL-1102 FDA, page-147

I don't subscribe to your Sarepta and AEF conspiracy theory, no one is out to sabotage the regulatory process and actively stop ATL1102 from being approved.

The value of a company is not determined by "attention and SP" and examining a company's " track record" in these areas is a pointless and misleading exercise.

Markie since you have such a unique view on things why don't you tell us what's in your portfolio? What companies do you like?

These "pointless FDA announcements" you keep trashing are actually just an early stage biotech trying to develop drugs for patients, and achieve regulatory approval. Orphan drug designation, rare pediatric disease designation, conversations with the FDA and EMA are all essential to this project.

The antisense team is hard at work trying to make a difference in sick kids lives, what are you doing with yours?

Trying to scare off potential investors, trashing company efforts, I don't think I've ever been in contact with someone as negative as you?